CD8A and cancer: Both the above described studies, using scRNA-seq either on cancer or immune cells of the TME, provided new insights on the crucial involvement of CD8+ T cells in driving resistance to immunotherapeutic agents, as well as suggested that specific transcriptomic signatures can predict the responders to immunotherapy, according to the state of the CD8+ T cells [41].